Armata Pharmaceuticals receives $3.7M in DoW funding to support AP-SA02 Phase 3

Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02.Key Highlights:Original SEC Filing: Armata Pharmaceuticals, Inc. [ ARMP ] - 8-K - Sep. 23, 2026This is an AI-powered summary. It may contain inac…